Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$68.98 USD
-2.71 (-3.78%)
Updated Oct 3, 2025 04:00 PM ET
After-Market: $69.00 +0.02 (0.03%) 7:58 PM ET
1-Strong Buy of 5 1
B Value D Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HALO 68.98 -2.71(-3.78%)
Will HALO be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for HALO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HALO
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease
HALO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Encompass Health Opens First Connecticut Rehab Hospital in Danbury
HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
Other News for HALO
Is HALO signaling selling opportunity? Fell Below 50 Day Moving Average shows up after sinking 3.78%
HALO forms 50 Day Moving Average Support on October 2
Halozyme Announces Merger Agreement with Elektrofi
Stochastic Buy Signal appears for HALO after 2.18% move
HC Wainwright & Co. Raises Price Target for Halozyme Therapeutics (HALO) | HALO Stock News